BMS drug Zenbexus cuts myeloma progression risk by 51% in trial
Tweet Send to a Friend
Bristol Myers Squibb (NYSE: BMY) announced positive topline results from its Phase 3 EXCALIBER-RRMM study, showing that Zenbexus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




